Glycopyrronium bromide (Seebri Breezhaler®)

Assessment Status Assessment process complete
HTA ID -
Drug Glycopyrronium bromide
Brand Seebri Breezhaler®
Indication As a maintenance bronchodilator treatment to relieve symptoms in patients with chronic obstructive pulmonary disease (COPD).
Assessment Process
Rapid review commissioned 12/08/2012
Rapid review completed 17/08/2012
Rapid review outcome Full Pharmacoeconomic Evaluation not Recommended.